Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 3,253 matching trials from the live ClinicalTrials.gov search.

Filters: Not yet recruiting Clear all

Conditions: Fibromyalgia
Interventions: Transcutaneous Vagus Nerve Stimulation; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Erythrocytosis, Pulmonary Hypertension, Thrombosis
Interventions: Belzutifan; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome
Interventions: Monzosertib, Posaconazole, Isavuconazole; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Genetic Predisposition, Type2diabetes
Interventions: Exendin 9-39, Saline; Biological · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 25 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Schizophrenia Spectrum Disorders
Interventions: GENUS, Sham Stimulation; Device
Lead sponsor: Massachusetts Institute of Technology; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: End Stage Kidney Disease
Interventions: Standard Table Salt, Salt Substitute; Dietary Supplement
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Evaporative Loss Dry Eye Disease
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Glaucoma
Interventions: Aflibercept Injection, Ahmed Tube Surgery; Drug · Procedure
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: IBS (Irritable Bowel Syndrome)
Interventions: Inulin, Low-fiber control breakfast shake, Atmo Gas-Sensing Capsule, CapScan Regional Fluid-Sampling Capsule; Dietary Supplement · Other · Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Stanford, California

Conditions: Vaso-Occlusive Pain Episode in Sickle Cell Disease, Sickle Cell Disease (SCD)
Interventions: Standardized Low-dose bolus IV Ketamine within 30 minutes of arrival and every 1 hour as needed for max of 3 doses., Standard Care (in control arm); Drug · Other
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 2 Years to 21 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Wound Closure, Wound Care
Interventions: Microlyte DualGuard, Allevyn Foam (Standard of Care Control); Device
Lead sponsor: Imbed Biosciences; Industry
Eligibility: 22 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • New Orleans, Louisiana

Conditions: Autism Spectrum Disorder (ASD)
Interventions: Standard Hospital Care, Telehealth Applied Behavior Analysis (TeleABA); Behavioral
Lead sponsor: Caring Technologies, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Neptune City, New Jersey • Somerset, New Jersey

Conditions: Obsessive-Compulsive Symptoms, Cognitive Control
Interventions: Cognitive Control Training; Device
Lead sponsor: Columbia University; Other
Eligibility: 8 Years to 12 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Asthma, Depression
Interventions: SAMBA, Cognitive Behavioral Therapy-Asthma Depression (CBT-AD), Original SAMBA; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 60 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Ovarian Cancer
Interventions: AST-201, Paclitaxel, Carboplatin, Placebo, rhuGM-CSF(Granulocyte-Macrophage Colony-Stimulating Factor); Biological · Drug
Lead sponsor: Aston Sci. Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Advanced Urothelial Carcinoma
Interventions: capivasertib; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 4
States / cities: West Haven, Connecticut • Boston, Massachusetts • Philadelphia, Pennsylvania + 1 more

Conditions: Sickle Cell Disease
Interventions: Music Therapy; Behavioral
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Lung Cancer (Diagnosis)
Interventions: Arm 1 "LipoB-I": Liposomal Bupivacaine via Multi-Level Intercostal Nerve Block, Arm 2 "LipoB-S": Liposomal Bupivacaine via Serratus Anterior Plane Block, Arm 3 "LipoB-C": Liposomal Bupivacaine Administered via Combination Block; Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Postpartum, Postpartum Depression (PPD), Hypertension Disorders in Pregnancy, Postpartum Anxiety, Postpartum Care, Care Coordination, Care Gaps
Interventions: Postpartum Doula Support in the NICU; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 18 Years and older · Female only
Enrollment: 756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 14
States / cities: Newark, Delaware • Voorhees Township, New Jersey • Bryn Mawr, Pennsylvania + 9 more

Conditions: Community Acquired Pneumonia (CAP)
Interventions: Ceftriaxone 1 gram daily, Ceftriaxone 2 grams daily; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 4
States / cities: Baltimore, Maryland • Glen Burnie, Maryland • Towson, Maryland

Conditions: CAR-T Cell Therapy, RSV Immunization, Bone Marrow Transplant - Autologous or Allogeneic
Interventions: Respiratory Syncytial Virus Prefusion F Vaccine (RSVpreF); Biological
Lead sponsor: Cooper Norcross Health; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Ventral Hernia, Incisional Hernia, Hernia, Hernia Abdominal Wall, Hernia Incisional, Hernia Incisional Ventral, Hernia of Abdominal Wall, Hernia Surgery
Interventions: Cryoneurolysis; Device
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Eosinophilic Esophagitis Caused by Food (Disorder)
Interventions: Assay directed diet change; Diagnostic Test
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 0 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Type 2 Diabetes
Interventions: Continuous glucose monitor; Device
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cincinnati, Ohio

Search by objective public record fields.

Toward Biomarker-Guided Fibromyalgia Treatment With Non-Invasive Vagus Nerve Stimulation

Phase IIA Study of Belzutifan in EPAS1-, EGLN1-, or VHL-Mutant Erythrocytosis

Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome

The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans

Gamma Light and Sound Stimulation in Schizophrenia

Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease

Decentralized Dry Eye Study, Planning & Feasibility

VGFTe-(HD)-OD-2566: Adjunctive Aflibercept Ahmed Glaucoma Valve (AAA) Study

High-Resolution Measurements of Diet-Microbiome Interactions

Low Dose Bolus Ketamine For Use In Sickle Cell Pain Crisis

Safety Study of Microlyte DualGuard

TeleABA for Hospitalized Adolescents and Young Adults With Autism Spectrum Disorder

Brain Function and Cognitive Control Training in Children With Obsessive-Compulsive Symptoms

R34 Asthma Depression

Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer

Immunotherapy Plus Capivasertib for Metastatic Bladder Cancer

Mechanisms Within the Autonomic Nervous SysTEm undeRlying MusIc Therapy's aNalgesic Effects in Sickle Cell Disease (MASTERMIND)

Combination Versus Alone Liposomal Bupivacaine Blocks in Minimally Invasive Thoracic Surgery-1

Postpartum Care in the NICU Multi-Site

Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia

RSV Vaccine Response in Stem Cell and CAR-T Therapy Recipients

Cryoneurolysis for Abdominal Wall Relaxation Prior to Ventral Hernia Repair

EoE Food Test Pilot Study

Transitioning Recently Admitted Patients With Non-Insulin and Insulin-treated Type 2 Diabetes to Innovative Glucose Monitoring